Enclosed are the Un-audited financial results (standalone and consolidated) for the quarter and nine months ended 31-Dec-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Elixir Capital Limited (Scrip: 531278) filed its unaudited Q3 FY26 and 9M FY26 results on Feb 13, 2026. On a standalone basis, the company slipped into a small loss of ₹0.99 lakh in Q3 (vs profit of ₹0.45 lakh in Q3 FY25), while 9M profit was nearly flat at ₹72.49 lakhs (vs ₹73.21 lakhs). Standalone total income for the quarter fell sharply to ₹3.64 lakhs as the previous quarter's one-off operating income of ₹74.68 lakhs did not recur. On a consolidated basis, Q3 income from operations more than doubled to ₹1,323.08 lakhs (vs ₹596.27 lakhs YoY, ~122% growth) and net profit jumped to ₹544.23 lakhs (vs ₹119.25 lakhs, ~356% growth), driven by subsidiaries Elixir Equities, Dipan Mehta Commodities, and Elixir Wealth Management. However, 9M consolidated revenue dipped 7.5% to ₹3,698.27 lakhs and net profit fell ~46% to ₹1,143.82 lakhs. Auditor JMT & Associates issued an unmodified (clean) review opinion on both sets of results.
Strong Q3 consolidated growth signals a sharp rebound, but the softer 9M numbers and a standalone quarterly loss show uneven performance through the year. The stock may react positively to the Q3 surge, but investors should note that consolidated 9M profits are still well below last year, so sustainability of the Q3 momentum is the key thing to watch.